Disc Medicine, Inc., together with its subsidiaries, operates as a clinical-stage biopharmaceutical company.

It engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.

The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders.

The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases.

The company was founded in 2017 and is headquartered in Watertown, Massachusetts.